COMMUNIQUÉS West-GlobeNewswire

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
07/02/2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results [...]
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07/02/2024
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye [...]
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
07/02/2024
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative [...]
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
07/02/2024
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companies Jonathan Yu, [...]
Stryker declares a $0.80 per share quarterly dividend
07/02/2024
Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the [...]
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
07/02/2024
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national [...]
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07/02/2024
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management [...]
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
07/02/2024
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with [...]
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
07/02/2024
The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 ROCKVILLE, Md., Feb. 07, [...]
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
07/02/2024
Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and [...]
New Survey Highlights Dire State of Nursing in 2024, Finds Optimism from Nurses Still in Profession
07/02/2024
IntelyCare's nationwide survey of nurses and nursing assistants points to workload, safety, care quality, and other concerns QUINCY, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- IntelyCare , a leading healthcare talent [...]
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
07/02/2024
BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results [...]
Evaxion annonce la clôture de son offre publique à 15 millions de dollars
07/02/2024
COPENHAGUE, Danemark, 07 févr. 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement [...]
Des chercheurs de KFSH&RC et de KAUST découvrent le gène responsable de la reproduction de la souche de paludisme la plus dangereuse qui soit
07/02/2024
RIYADH, Arabie saoudite, 07 févr. 2024 (GLOBE NEWSWIRE) -- Il s’agit là d’une véritable découverte scientifique : en collaboration avec l’université des sciences et technologies du roi Abdallah (« KAUST ») et aux côtés [...]
VALNEVA: Declaration of shares and voting rights - January 31, 2024
07/02/2024
VALNEVA Declaration of shares and voting rights January 31, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA : Déclaration d’actions et de droits de vote - 31 janvier 2024
07/02/2024
VALNEVA Déclaration d’actions et de droits de vote 31 janvier 2024 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
119,021 Orion Corporation A shares converted into B shares
07/02/2024
ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 FEBRUARY 2024 at 9.30 EEST 119,021 Orion Corporation A shares converted into B shares In accordance with [...]
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
07/02/2024
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to [...]
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
07/02/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III [...]

Pages